Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Adverse events following COVID-19 vaccination in young Japanese people: A case-control study of the risk of systemic adverse events by a questionnaire survey

Marie Suehiro, Shinya Okubo, Kensuke Nakajima, Kosuke Kanda, Masanobu Hayakawa, Shigeru Oiso, Tsutomu Kabashima, Hideaki Fujita, Yukio Ando, Takahiro Muro
doi: https://doi.org/10.1101/2021.10.01.21264393
Marie Suehiro
1Division of Medical Informatics, Department of Pharmacy, Faculty of Pharmaceutical Sciences, Nagasaki International University, Japan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinya Okubo
2Division of Pharmaceutical Health Care and Science, Department of Pharmacy, Faculty of Pharmaceutical Sciences, Nagasaki International University, Japan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kensuke Nakajima
2Division of Pharmaceutical Health Care and Science, Department of Pharmacy, Faculty of Pharmaceutical Sciences, Nagasaki International University, Japan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kosuke Kanda
3Division of Clinical Pharmaceutics, Department of Pharmacy, Faculty of Pharmaceutical Sciences, Nagasaki International University, Japan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masanobu Hayakawa
3Division of Clinical Pharmaceutics, Department of Pharmacy, Faculty of Pharmaceutical Sciences, Nagasaki International University, Japan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shigeru Oiso
2Division of Pharmaceutical Health Care and Science, Department of Pharmacy, Faculty of Pharmaceutical Sciences, Nagasaki International University, Japan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsutomu Kabashima
4Division of Pharmaceutical Technology, Department of Pharmacy, Faculty of Pharmaceutical Sciences, Nagasaki International University, Japan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hideaki Fujita
5Section of Functional Morphology, Department of Pharmacy, Faculty of Pharmaceutical Sciences, Nagasaki International University, Japan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yukio Ando
6Division of Amyloidosis Research, Department of Pharmacy, Faculty of Pharmaceutical Sciences, Nagasaki International University, Japan
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takahiro Muro
1Division of Medical Informatics, Department of Pharmacy, Faculty of Pharmaceutical Sciences, Nagasaki International University, Japan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: muroth@niu.ac.jp
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Summary

What is known and objective Racial differences in adverse events following COVID-19 vaccines have not been sufficiently studied. Here, we aimed to study the adverse events of Moderna’s intramuscular COVID-19 vaccine in young Japanese people.

Methods A case-control study was conducted using a questionnaire survey. Risk factors were determined using a multivariable logistic regression model. We also compared the occurrence of systemic adverse events in three pairs (minor and adult; male and female; and occurrence and non-occurrence of adverse events after the first dose). Propensity matching was used to balance variables.

Results We analysed 3,369 data points (1,877 after the first dose and 1,492 after the second dose) obtained from a questionnaire survey of 7,965 vaccinated individuals. Comparing the results of the first and second doses, the incidence of local adverse events did not change significantly; however, the incidence of systemic adverse events increased significantly (p < 0.001). Eighty-three percent of the participants complained of local adverse events, and 65% of participants complained of systemic adverse events. Anaphylaxis occurred in one female student (0.03%). Even when an adverse event occurred, most of the symptoms improved within 3 days. Female sex was associated with systemic adverse events after the first and second doses with odds ratios (ORs) (95% confidence interval, CI) of 2.49 (2.03–3.06), and 1.83 (1.28–2.61), respectively. Age (<20 years: minor) was associated with systemic adverse events after the first dose with an OR of 1.80 (1.44–2.24).

The results of the analysis of six cohorts that were created using propensity score matching showed that the incidence of systemic adverse events at the first dose in females was significantly higher than that in males, and that of minors was significantly higher than that of adults.

What is new and conclusion The results of this study clarified, for the first time, the risk factors for several adverse events from the injection of Moderna’s intramuscular COVID-19 vaccine in young Japanese people.

This study suggests that women, minors who experienced adverse events after the first dose, those who experienced adverse events after the first dose, and those who had adverse events after the second dose, should be aware of adverse events.

What is known and objective The COVID-19 crisis has been spreading worldwide, and the number of infected people is increasing due to the emergence of mutant strains. The COVID-19 vaccine is expected to be effective in preventing coronavirus infection and disease aggravation.

In Japan, priority groups, such as healthcare workers and the older adults (aged 65 and over), were the first to be vaccinated. Workplace vaccinations began on 21 June 2021 at universities and businesses; university employees and students have also been vaccinated.

In June 2021, in Japan, Moderna’s intramuscular injection of the COVID-19 vaccine was used for vaccination in places associated with students and corresponding teaching staff. However, as of September 2021, the Comirnaty intramuscular injection vaccine had been used for healthcare workers and elderly people ahead of other COVID-19 vaccines.

Adverse events of the Comirnaty intramuscular injection vaccine in healthcare workers and elderly people and that of Moderna’s intramuscular COVID-19 vaccine in the defence forces, who were prioritised for administration, are currently being studied. However, adverse events associated with the intramuscular injection of Moderna’s COVID-19 vaccine in young people have not yet been well studied in Japan. 1,2. In addition, racial differences in adverse events following coronavirus vaccines have not been sufficiently studied.

We have already reported adverse events associated with the first dose of Moderna’s intramuscular injection of its COVID-19 vaccine. In Japan, the intramuscular injection of Moderna’s COVID-19 vaccine will continue to be used in large-scale inoculation venues such as universities and workplaces.

Therefore, to clarify the adverse events following coronavirus vaccination in the young Japanese population, we conducted a questionnaire survey after the second dose for students, faculty, and staff who belong to an educational foundation, Kyushu Bunka Gakuen.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

We do not receive external funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Nagasaki International University Ethics Committee (approval number 50, 2 July 2021).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Data availability statement

  • Conflict of Interest The authors have no conflicts of interest to declare regarding this study.

  • Source of Funding: No funding was provided for this study.

  • Ethics approval statement This study was approved by the Nagasaki International University Ethics Committee (approval number 50, 2 July 2021).

  • Patient consent statement The Japanese Ethics Guidelines for Epidemiological Studies stipulate that the use of existing medical records in observational studies can be used without the consent of individual patients by disclosing information about the purpose and conduct of the study and guaranteeing the opportunity for refusal. An explanation of this study is provided on the website of the Nagasaki International University. Consent to participate in the questionnaire was obtained individually.

Data Availability

Due to the nature of this research, participants of this study did not agree for their data to be shared publicly, so supporting data is not available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted October 05, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Adverse events following COVID-19 vaccination in young Japanese people: A case-control study of the risk of systemic adverse events by a questionnaire survey
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Adverse events following COVID-19 vaccination in young Japanese people: A case-control study of the risk of systemic adverse events by a questionnaire survey
Marie Suehiro, Shinya Okubo, Kensuke Nakajima, Kosuke Kanda, Masanobu Hayakawa, Shigeru Oiso, Tsutomu Kabashima, Hideaki Fujita, Yukio Ando, Takahiro Muro
medRxiv 2021.10.01.21264393; doi: https://doi.org/10.1101/2021.10.01.21264393
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Adverse events following COVID-19 vaccination in young Japanese people: A case-control study of the risk of systemic adverse events by a questionnaire survey
Marie Suehiro, Shinya Okubo, Kensuke Nakajima, Kosuke Kanda, Masanobu Hayakawa, Shigeru Oiso, Tsutomu Kabashima, Hideaki Fujita, Yukio Ando, Takahiro Muro
medRxiv 2021.10.01.21264393; doi: https://doi.org/10.1101/2021.10.01.21264393

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1747)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (653)
  • Epidemiology (10780)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2933)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1918)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12496)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (321)
  • Neurology (2780)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (554)
  • Occupational and Environmental Health (597)
  • Oncology (1454)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (379)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2630)
  • Public and Global Health (5338)
  • Radiology and Imaging (1002)
  • Rehabilitation Medicine and Physical Therapy (594)
  • Respiratory Medicine (722)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)